Key Points
- Director Robert Malenka sold 7,039 shares on Feb. 2 at an average price of $18.02 for $126,842.78, leaving him with 358,234 shares (a 1.93% reduction) valued at roughly $6.46 million.
- Maplight reported a dramatic quarterly loss of ($37.18) EPS
- Analysts are mixed but the street consensus is a "Moderate Buy" with an average price target of $31.00 (ratings: 1 Strong Buy, 3 Buy, 1 Hold, 1 Sell).
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) Director Robert Malenka sold 7,039 shares of the company's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.02, for a total value of $126,842.78. Following the transaction, the director directly owned 358,234 shares in the company, valued at approximately $6,455,376.68. This represents a 1.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Maplight Therapeutics Stock Performance
Shares of MPLT stock opened at $16.80 on Thursday. The firm has a market capitalization of $762.27 million and a price-to-earnings ratio of -0.45. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $21.55. The stock has a 50-day moving average price of $17.88.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).
Analyst Ratings Changes
A number of brokerages recently commented on MPLT. Leerink Partners started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an "outperform" rating and a $30.00 price objective for the company. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a "buy" rating and a $28.00 target price for the company. Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued a "buy" rating and a $32.00 price target on the stock. Zacks Research upgraded shares of Maplight Therapeutics to a "hold" rating in a report on Monday, November 24th. Finally, Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a "sell (e)" rating on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Maplight Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $31.00.
Read Our Latest Stock Report on MPLT
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Maplight Therapeutics stock. Strs Ohio purchased a new position in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,000 shares of the company's stock, valued at approximately $53,000.
Maplight Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
